Vertex Pharmaceuticals Inc
VRTXHealthcare|Biotechnology|USA
$434.30
-4.41 (-1.01%)
DCF (FCF)
$183.42
Tangible Book
$67.54
Graham Number
$167.26
Earnings Power
$127.09
About
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Stock Price
-10.3%(1Y)
Pipeline Summary
283 total trials87
Phase 1
89
Phase 2
94
Phase 3
6
Phase 4
Completed: 221Recruiting: 17Terminated: 21Active: 9Unknown: 1ENROLLING_BY_INVITATION: 3NOT_YET_RECRUITING: 2APPROVED_FOR_MARKETING: 4Withdrawn: 5
Active Trials (26)
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741Cystic Fibrosis
Phase 1Phase 2Recruiting
Enrollment: 39 participants
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active
Enrollment: 401 participants
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649Sickle Cell Disease
Phase 3Active
Enrollment: 13 participants
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506Cystic Fibrosis
Phase 3Active
Enrollment: 50 participants
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
NCT05312879Proteinuric Kidney Disease
Phase 2Phase 3Recruiting
Enrollment: 466 participants
BioScore
7.4/10
Buy
Ownership
Recent Insider Trades
Liu JoySELL
2026-04-01978 shares @ $449.17
Bozic CarmenSELL
2026-03-272,329 shares @ $450.95
Bozic CarmenSELL
2026-03-132,329 shares @ $481.79
McKechnie DuncanSELL
2026-03-112,633 shares @ $498.42
McKechnie DuncanSELL
2026-03-042,437 shares @ $475.3
Recent News
2026-04-06 21:00:02
2026-04-03 22:01:28
2026-04-01 20:30:16
2026-04-01 12:28:30
2026-04-01 12:00:08
Data last updated: Apr 7, 2026, 03:33 AM